Phrontline's TJ101 Gains Momentum in Cancer Clinical Trials
Encouraging Signs from Phrontline's TJ101 ADC Trials In the high-stakes race to outsmart cancer, Phrontline Biopharma is banking on TJ101, their star investigational bispecific antibody-drug conjugate (ADC). The recent results shared at the ESMO Congress 2026 are stirring up quite a bit of chatter. Urothelial Carcinoma and Beyond Now, picture this: six of eight evaluable...
Continue Reading